

Submission” or “More Search Options” to find the information collection document(s) accepting comments.

2. *By regular mail.* You may mail written comments to the following address: CMS, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development, Attention: Document Identifier/OMB Control Number \_\_\_\_\_, Room C4-26-05, 7500 Security Boulevard, Baltimore, Maryland 21244-1850.

Dated: January 25, 2008.

**Michelle Shortt,**

*Director, Regulations Development Group,  
Office of Strategic Operations and Regulatory Affairs.*

[FR Doc. E8-1810 Filed 1-31-08; 8:45 am]

BILLING CODE 4120-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### President's Committee for People With Intellectual Disabilities; Notice of Quarterly Meeting

**AGENCY:** President's Committee for People with Intellectual Disabilities (PCPID); Administration for Children and Families; Department of Health and Human Services.

**ACTION:** Notice of Quarterly Meeting.

**DATES:** February 15, 2008, from 3:30 p.m. to 5:30 p.m. EST. The meeting will be conducted via conference call and will be open to the public using the dial-in information provided below.

**ADDRESSES:** The conference call may be accessed on the date and time indicated by dialing 888-677-5720, passcode: 1397797.

**Agenda:** PCPID will meet to finalize the 2007 Report to the President and to hear a briefing on the final report of the Ticket to Work and Work Incentives Advisory Panel.

#### FOR FURTHER INFORMATION CONTACT:

Sally D. Atwater, Executive Director, President's Committee for People with Intellectual Disabilities, The Aerospace Center, Second Floor, West, 370 L'Enfant Promenade, SW., Washington, DC 20447. Telephone: 202-619-0634, Fax: 202-205-9591. E-mail: [satwater@acf.hhs.gov](mailto:satwater@acf.hhs.gov).

**SUPPLEMENTARY INFORMATION:** PCPID acts in an advisory capacity to the President and the Secretary of Health and Human Services on a broad range of topics relating to programs, services and supports for persons with intellectual disabilities. PCPID, by

Executive Order, is responsible for evaluating the adequacy of current practices in programs, services and supports for persons with intellectual disabilities, and for reviewing legislative proposals that impact the quality of life experienced by citizens with intellectual disabilities and their families.

Dated: January 25, 2008.

**Sally D. Atwater,**

*Executive Director, President's Committee for People with Intellectual Disabilities.*

[FR Doc. E8-1809 Filed 1-31-08; 8:45 am]

BILLING CODE 4184-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Request for Notification from Industry Organizations Interested in Participating in the Selection Process for a Nonvoting Industry Representative on the Blood Products Advisory Committee and Request for Nominations for a Nonvoting Industry Representative on the Blood Products Advisory Committee

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is requesting that any industry organizations interested in participating in the selection of a nonvoting industry representative to serve on the Blood Products Advisory Committee, Center for Biologics Evaluation and Research (CBER), notify FDA in writing. A nominee may either be self-nominated or nominated by an organization to serve as a nonvoting industry representative. Nominations will be accepted for an upcoming vacancy on September 30, 2008, effective with this notice.

**DATES:** Any industry organization interested in participating in the selection of an appropriate nonvoting member to represent industry interests must send a letter stating the interest to FDA by March 3, 2008, for vacancies listed in the notice. Concurrently, nomination material for prospective candidates should be sent to FDA by March 3, 2008.

**ADDRESSES:** All letters of interest and nominations should be submitted in writing to Donald W. Jehn (see **FOR FURTHER INFORMATION CONTACT**).

**FOR FURTHER INFORMATION CONTACT:** Donald W. Jehn, Division of Scientific Advisors and Consultants, Center for Biologics Evaluation and Research,

Food and Drug Administration (HFM-71), 1401 Rockville Pike, Rockville, MD 20892, 301-827-1277, [donald.jehn@fda.hhs.gov](mailto:donald.jehn@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** The agency requests nominations for a nonvoting industry representative to the Blood Products Advisory Committee.

### I. Function

The Blood Products Advisory Committee reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood products derived from blood and serum or biotechnology which are intended for the use in the diagnosis, prevention, or treatment of human diseases, and, as required, any other product for which FDA has regulatory responsibility. The committee also advises the Commissioner of Food and Drugs (the Commissioner) on its findings regarding the safety, effectiveness, and labeling of the products, clinical and laboratory studies involving such products, the affirmation or revocation of biological product licenses, and on the quality and relevance of FDA's research program which provides the scientific support for regulating these agents.

### II. Selection Procedure

Any blood products industry, association, or organization interested in the selection of an appropriate nonvoting member to represent industry interests should send a letter stating that interest to the FDA contact (see **FOR FURTHER INFORMATION CONTACT**) within 30 days of publication of this document (see **DATES**). Within the subsequent 30 days, FDA will send a letter to each organization that has expressed an interest, attaching a complete list of all such organizations and a list of all nominees along with their current resumes. The letter will also state that it is the responsibility of the interested organizations to confer with one another and to select a primary and alternate candidate, within 60 days after the receipt of the FDA letter, and the primary candidate will serve as the nonvoting member to represent industry interests for the Blood Products Advisory Committee. The interested organizations are not bound by the list of nominees in selecting a candidate. However, if no individual is selected within 60 days, the Commissioner will select the nonvoting member to represent industry interests.

### III. Application Procedure

Individuals may self nominate and/or an organization may nominate one or more individuals to serve as a nonvoting